Navigation Links
Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors
Date:4/10/2008

Company's Board Expanded to Seven Members

DALLAS, April 10, /PRNewswire-FirstCall/ -- Crdentia Corp. (OTC Bulletin Board: CRDT), a leading healthcare staffing company, today said that its Board of Directors has elected David Jenkins and Raymond (Jay) Dunn to its Board of Directors, effective immediately. This announcement expands the Company's Board of Directors to seven members.

John Kaiser, Crdentia's President and Chief Executive Officer, said, "I am delighted David and Jay have joined Crdentia's Board of Directors. Each has tremendous depth of knowledge, healthcare expertise and public company experience that now can accrue to the benefit of Crdentia. With this announcement, the strength of our board is further enhanced, and we look forward to contributions from David and Jay as we continue our efforts to execute our strategic initiatives to improve Crdentia's operations and profitably grow our business."

Mr. Jenkins is currently the managing member and general partner of FatBoy Capital, LLC, a shareholder of Crdentia. In addition, Mr. Jenkins is also a Director of EP MedSystems, Inc. (Nasdaq: EPMD), a medical technology company that develops, manufactures and markets cardiac rhythm management and electrophysiology products, which are used to diagnose, monitor, visualize and treat irregular heartbeats known as arrhythmias. EP MedSystems, Inc. recently announced an agreement to be acquired by St. Jude's Medical, Inc. Mr. Jenkins has also served as President and a director of Transneuronix, Inc., a privately-held company engaged in the development of neuromuscular stimulation devices, until its sale to Medtronic Inc. in 2005. He is currently a director of Inset Technologies, Inc. and Catheter Robotics,
'/>"/>

SOURCE Crdentia Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
2. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
3. Crdentias National Director of Travel Services Provides an Exclusive Interview on the Growth of Crdentias Travel Nurse Division
4. Crdentia Acquires ATS Health Services
5. Crdentia Announces Completion of $5M Financing
6. Crdentia Announces Appointment of Tim Jones to Senior Management Team
7. Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources
8. Crdentia Appoints Debbie Griffith to Director of Business Development, Reporting Directly to CEO
9. Crdentia Appoints Charlie Mayhone to Director of Operations for its National Travel Division and Charlotte, North Carolina Market
10. Crdentia Promotes Kevin Bollin to Area Manager of Austin, Dallas and San Antonio, Texas, Markets
11. Investor Insight Initiates Analyst Coverage on Crdentia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3UC Davis study highlights work life issues of female surgeons 52395 1UC Davis study highlights work life issues of female surgeons 52395 2Fecal incontinence and quality of life 52393 1Early rice harvests ease annual famine in Bangladesh 9316 1Early rice harvests ease annual famine in Bangladesh 9316 2